Healthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study
Open Access
- 9 February 2023
- journal article
- research article
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 7 (3)
Abstract
Background: Poor asthma control is associated with high short-acting β2-agonist (SABA) use.Aim: To assess asthma-related healthcare resource utilisation (HCRU) and medication costs associated with high versus low SABA prescriptions in the UK.Design & setting: Analysis of SABINA I (SABA use IN Asthma I), a retrospective longitudinal study using UK electronic health records (Clinical Practice Research Datalink GOLD 2008−2019 and Hospital Episode Statistics database).Method: Eligible patients were ≥12 years old with SABA prescriptions in the past year. SABA prescriptions (number of canisters per year) were defined as high (≥3) or low (1–2). Association of SABA prescriptions with HCRU was assessed by negative binominal model adjusted for covariates. The UK unit costs from the NHS were applied to estimate total healthcare costs (2020). Medication costs were based on the annual average number of canisters per year per patient.Results: Overall, 186 061 patients with SABA prescriptions were included, of whom 51% were prescribed high SABA. Total annual average costs (HCRU and medication) were 52% higher in the high SABA group versus the low SABA group (£2 256 091 per 1000 patients/year versus £1 480 640 per 1000 patients/year). Medication costs accounted for the majority of asthma-related costs. Across both groups, most HCRU costs were for non–exacerbation-related primary care or hospital outpatient visits. The annual average HCRU cost difference for high SABA versus low SABA was the greatest for hospitalisations (+230%; £15 521 per 1000 patients/year versus £4697 per 1000 patients/year) and exacerbation-related primary care visits (+162%; £18 770 per 1000 patients/year versus £7160 per 1000 patients/year). Asthma-related HCRU extrapolated to the broader UK asthma population was £108.5 million per year higher with high SABA versus low SABA.Conclusion: High SABA versus low SABA prescriptions are associated with higher asthma-related HCRU costs.Keywords
This publication has 40 references indexed in Scilit:
- Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North AmericaThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Usage Patterns of Short-Acting β2-Agonists and Inhaled Corticosteroids in Asthma: A Targeted Literature ReviewThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global ProgramAdvances in Therapy, 2020
- SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European CountriesAdvances in Therapy, 2020
- Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United StatesAnnals of Allergy, Asthma & Immunology, 2019
- The projected economic and health burden of sub-optimal asthma control in CanadaRespiratory Medicine, 2018
- The impact of inappropriate use of short acting beta agonists in asthmaRespiratory Medicine, 2017
- Short-acting β-agonist use and its ability to predict future asthma-related outcomesAnnals of Allergy, Asthma & Immunology, 2012
- Asthma control in Europe: A real-world evaluation based on an international population-based studyJournal of Allergy and Clinical Immunology, 2007
- Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthmaJournal of Allergy and Clinical Immunology, 2004